Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Cash from Financing Activities (2019 - 2025)

Avidity Biosciences (RNA) has disclosed Cash from Financing Activities for 7 consecutive years, with -$5.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities fell 137.06% year-over-year to -$5.1 million, compared with a TTM value of $851.0 million through Dec 2025, down 28.63%, and an annual FY2025 reading of $851.0 million, down 28.63% over the prior year.
  • Cash from Financing Activities was -$5.1 million for Q4 2025 at Avidity Biosciences, down from $850.4 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $850.4 million in Q3 2025 and bottomed at -$5.1 million in Q4 2025.
  • Average Cash from Financing Activities over 5 years is $133.0 million, with a median of $28.0 million recorded in 2022.
  • The sharpest move saw Cash from Financing Activities skyrocketed 856060.0% in 2024, then plummeted 137.06% in 2025.
  • Year by year, Cash from Financing Activities stood at $20.7 million in 2021, then soared by 1076.28% to $243.7 million in 2022, then tumbled by 86.91% to $31.9 million in 2023, then plummeted by 56.97% to $13.7 million in 2024, then tumbled by 137.06% to -$5.1 million in 2025.
  • Business Quant data shows Cash from Financing Activities for RNA at -$5.1 million in Q4 2025, $850.4 million in Q3 2025, and $3.8 million in Q2 2025.